Monkeypox Vaccine Study Raises Questions About Protection

• Bavarian Nordic’s Jynneos vaccine spurred low antibody levels
• Research suggests dose-sparing approach reduces virus immunity

The monkeypox vaccine that’s become the main method doctors are using to try to stop the global scourge may be less potent than hoped, new research shows.   

The recommended series of shots with Bavarian Nordic A/S’s Jynneos vaccine yielded relatively low levels of monkeypox antibodies with poor neutralizing capacity, researchers at the Erasmus University Medical Center in Rotterdam, Netherlands, said. Those immunized hadn’t been previously infected or vaccinated against smallpox, which is believed to provide some protection against monkeypox. 

https://www.bloomberg.com/news/articles/2022-09-02/monkeypox-vaccine-study-raises-questions-about-protection